T he huge discrepancy between the cadaver kidney availability and the increasing number of candidates on waiting lists underscores the need to consider all available donors, including those with an increased risk of disease transmission. Despite attempts to reduce the organ shortage, potential donors are still excluded from organ donation due to the fear of viral transmission to the recipients.
Livers procured from donors with a past hepatitis B virus (HBV) infection serological profile (HBsAg negative (Ϫ), anti-HBc positive (ϩ), and/or anti-HBs ϩ ) are considered a high risk for transmission of HBV infection (1) (2) (3) (4) . The impact of antibodies to hepatitis B core (HBc) in renal transplantations, however, appears low to negligible (5) (6) (7) (8) . All the published studies to date are retrospective and predominantly based on a small number of patients (1, 2, (5) (6) (7) with the exception of the United Network of Organ Sharing analysis (8) . This subject is a matter of particular interest in Italy, a country with a high prevalence of hepatitis B infection (9) , where until 2002 anti-HBc determinations were not mandatory. To evaluate the prevalence of anti-HBc ϩ donor kidneys and the incidence of HBV transmission, based on the recipients' HBV status before transplantation, we retrospectively tested sera from 886 cadaver donors used for transplantation during the period spanning 1997-1999, the years preceding government required anti-HBc screening, in the North Italy Transplant program (NITp) (10) .
PATIENTS AND METHODS

The North Italy Transplant Program
NITp is an organ procurement and transplant coordinating organization, located in Milan, which serves an area with 18 million inhabitants in the North of Italy. It is coordinated by a single reference center. NITp was established in 1972 and currently includes about 60 hospitals procuring organs and 39 transplant centers (10) .
Methods of Investigation
Serum collected from donors referred to the NITp between January 1997-December 1999 was retrospectively tested for the presence of anti-HBc antibodies. If the serum tested positive for these antibodies, the anti-HBs of the respective donors was evaluated. The sera were selected only on the basis of availability of a sample stored in our repository. The presence of anti-HBc and anti-HBs antibodies were determined using two Microparticle Enzyme Immunoassays (MEIA) produced by Abbott (Abbott Park, IL), the Imx CORE and Imx AUSAB, respectively.
We also determined the incidence of HBV transmission among recipients of transplanted kidneys procured from anti-HBc ). Vaccinated and recovered patients were also reported as "immune." The presence of HBsAg was assayed at least once a year after transplantation, whereas anti-HBc and anti-HBs were tested for the purpose of the study. Recipients' sera were tested using routine methods employed at each transplant centre. Transmission of HBV infection was defined as the presence of posttransplant HBsAg positive sera in recipients HBsAg -and anti-HBc -prior to the transplant after excluding all other possible sources of HBV infection. In addition, the 5-year survival rates of graft and patients transplanted with kidneys from anti-HBc ϩ (Dϩ) or anti-HBc -(D-) donors were also analyzed.
Statistical Analysis
We performed a univariate analysis to determine the influence on kidney graft survival and function of the following factors: donor age, recipient age, donor-recipient age match, occurrence of previous kidney graft, panel reactive antibody (PRA), occurrence of pretransplant transfusions, and the number of HLA-A, B, and DRB1 mismatches. Patient and graft survival curves were calculated using the actuarial method. The independent contribution of donor and recipient age, donor/recipient gender match, donor's anti-HBc (positive or negative), cause of donor's death, transfusion of donor, PRA, transfusion of donor ABO blood group, HLA mismatch, and cold ischemia time on patient and graft survival were evaluated by multivariate analysis (proportional hazard model [PHREG] ). P values Յ 0.05 were considered statistically significant. The Fisher's test was used to compare categorical variables. The variable representing two combinations of donor and recipient anti-HBc test results was included in the multivariate analysis (Dϩ/Recipient (R)-, Dϩ/ Rϩ). All data were analyzed with the Statistical Analysis System Package (SAS Institute, Cary, NC).
RESULTS
Sera were available for testing from 886 (92%) of the 964 HBsAg -and anti-HCV -cadaver donors. Two hundred and ten were anti-HBc ϩ and the remaining 676 donors were anti-HBc -. Among the positive donors, 25 were anti-HBc ϩ / anti-HBs -and 185 were anti-HBc ϩ /anti-HBs ϩ . Sera were collected either before transfusions or from non-transfused donors in 103 (49%) of the 210 HBc ϩ sera, and the remaining 107 samples were from donors transfused during an intensive care unit stay.
Three hundred and fifty-nine kidneys procured from the 210 anti-HBc ϩ donors were transplanted into 356 patients (three patients received a double kidney graft according to the NITp double kidney transplant protocol).
The 676 anti-HBc -donors provided 1,110 kidneys that were transplanted into 1,103 recipients (seven double-kidney transplants). Donor and recipient characteristics are reported in Table 1 
DISCUSSION
HBV transmission by organs procured from HBsAg or anti-HBc IgM ϩ donors has been reported as a negative prognostic factor for survival of kidney transplant recipients (11, 12) . Recently, several studies have reported that donors with a serological profile indicating a past HBV infection are at risk of transmitting HBV to their recipients (1, 2, 8, 13, 14) .
No data have been reported on Italian transplanted patients. Anti-HBc testing was not mandatory in Italy until 2002 and as a consequence many transplants were performed regardless of donor anti-HBc status prior to 2003. As the donor's anti-HBc status was evaluated for the purpose of this study, our analysis allows an accurate estimate of the actual risk of HBV transmission according to the recipient's HBV serostatus; for example vaccinated, nonvaccinated, or naïve.
We did not find any recipient who acquired a positive hepatitis B surface antigen. This finding is consistent with previous reports (1, 8, 13 ) which found a negligible risk of HBV transmission from transplanting kidneys from antiHBc ϩ donors. Although small amounts of hepdnaviral DNA have been found in animal models in kidney, pancreas and mononuclear cells, hepadnaviruses have a strong preference for infecting liver cells and infection at these sites is not linked to extra-hepatic disease (15) . A confirmation of this hypothesis is reported in the study by Wachs (1) where an antiHBcϩ multiorgan donor transmitted HBV to the liver allograft recipient but no apparent transmission to the two kidney allograft recipients.
Despite the absence of HBsAg seroconversion in our series, 4/140 vaccinated subjects seroconverted from antiHBc -to anti-HBc ϩ and yet presented no clinical or biochemical signs of hepatitis. This finding, somewhat unexpected, is in agreement with the percentage of seroconversion reported by Fong and colleagues (8) , although data on the vaccination status were not provided.
Due to the retrospective nature of this study, we can only speculate on the cause of this unusual finding. The more likely explanation is that because these four patients were found to be anti-HBcϩ 4 years after transplantation, they may have lost their protective anti-HBs titer and therefore experienced an asymptomatic HBV hepatitis. This may have occurred regardless of the donor's HBV serology, with a spontaneous clearance of the HBsAg and persistence of antiHBc. Reactivation of an occult HBV infection, documented in solid organ and bone marrow transplantation (16), seems unlikely.
Graft and patient survival rates in the D-/R-group were not significantly different from that of Dϩ/R-group evaluated either by the univariate or multivariate analysis. This finding was contradictory to the results of Fong et al. (8) , which demonstrated that graft and patient survival at 1 and 3 years were significantly decreased for recipients transplanted from anti-HBcϩ donors compared to those from anti-HBc -donors. However, in a multivariate analysis the lower survival rate was related to donor and recipient factors independent of the anti-HBc status. The discrepancy could be attributed to the fact that in our series the distribution of variables that could affect patient survival did not significantly differ in the two populations of anti-HBc negative and positive donors. This may have eliminated the effect of comorbidity factors evidenced in the Fong study.
Anti-HBc ϩ was prevalent in 24% of the population of cadaver donors considered. This high a percentage is comparable to that of a geographic area endemic for HBV infection (17, 18) , but could have been biased by the serum collection time. Nearly 50% of organ donors were transfused prior to anti-HBc testing, in addition, Italy differs from other countries (8) in that anti-HBc screening is not required for blood donors. These points underline the importance of testing se- rum samples collected before blood component administration to avoid misleading results. A recent retrospective study conducted with Italian blood donors indicates that the estimated incidence for total HBV infection is high compared to other countries in Europe (9.77 per 100.000 person/year) (19) . Until recently however, anti-HBc testing of organ donors was not mandatory and organs from anti-HBc ϩ donors could be transplanted. On the basis of a few reports of de novo hepatitis infections after solid organ transplantation, especially occurring in liver transplants, a panel of experts at the Italian Ministry of Health developed guidelines in the last months of 2002 that allow the use of anti-HBc ϩ organs for only selected patients and naive patients who have given informed consent. As a consequence of this, kidneys are preferentially allocated to vaccinated recipients. Furthermore, the requirement for informed consent generates concern amongst the recipients and potential candidates refuse to undergo transplantation due to the fear of HBV transmission. This is an important issue for patients and doctors involved in the transplantation of kidneys in Italy considering the high incidence of anti-HBc ϩ donors. No cases of HBV infection have been found in vaccinated recipients based on our results and previous work (2) . This suggests that HBV vaccination should be mandatory for all patients admitted to the kidney waiting list.
In conclusion, this retrospective study evaluating a large cohort of transplant patients in a HBV endemic country indicated that the risk of hepatitis B transmission through 
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ϩ kidney transplants was negligible. On the basis of our data, we suggest less restrictive Guidelines for non-immune patients because the benefits obtained following transplantation out-number the risks of HBV transmission.
